A sole source acquisition is justified because Bruker Daltonics, Inc., is the only analytical instrument accessories that will meet our technical requirement. There are no other suppliers that will satisfy our analytical requirement for protein toxin measurements. The acquisition from Bruker Daltonics, Inc., provides continuity and standardization for the protein toxin detection. Also, allows Bruker Daltonics, Inc., to maintain productivity, reduce time needed for training, and take advantage of configuration management features used on other current systems.
CDC intends to negotiate this requirement with Bruker Daltonics, Inc., under the authority of FAR 13.106-1(b) (1), Only One Responsible Source, and 41 U.S.C. 253(c) (1). Bruker Daltonics, Inc., is the only source available to provide these services and meet the Agency's critical requirement. This notice of intent is not a request for competitive proposals or quotations. A determination to compete this procurement based on responses to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement as described above. All responses should be received by March 13, 2017, at 10AM, Eastern Standard Time (EST). All responses must be in writing and can be sent via email to [email protected] with the reference number 2017-Q-66409 in the subject line. No telephone calls will be accepted.